We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.05 | 0.55% | 9.15 | 1,054,095 | 12:15:26 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 8.80 | 9.50 | 9.15 | 8.86 | 9.10 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.09 | 84.9M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:07:32 | O | 200,000 | 9.15 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/4/2024 | 07:00 | UK RNS | Scancell Holdings Plc Presenting at the Annual Immuno-Oncology Summit |
| 16/4/2024 | 07:00 | UK RNS | Scancell Holdings Plc Block Listing Six Monthly Return |
| 03/4/2024 | 07:00 | UK RNS | Scancell Holdings Plc Employee exercise of share options |
| 02/4/2024 | 07:00 | UK RNS | Scancell Holdings Plc Scancell to Present at 2024 AACR Annual Meeting |
| 28/3/2024 | 13:21 | UK RNS | Scancell Holdings Plc Scancell Appoints WG as Joint Broker |
| 26/3/2024 | 14:00 | ALNC |  Scancell doses first patient in melanoma-focused trials |
| 26/3/2024 | 12:22 | UK RNS | Scancell Holdings Plc First iSCIB1+ patient dosed |
| 14/3/2024 | 11:17 | UK RNS | Scancell Holdings Plc Appointment of Sath Nirmalananthan to the Board |
| 12/3/2024 | 07:00 | UK RNS | Scancell Holdings Plc Scancell Attendance at Upcoming Conferences |
| 04/3/2024 | 07:00 | UK RNS | Scancell Holdings Plc Presenting at Next-Gen Immuno-Oncology Conference |
Scancell (SCLP) Share Charts1 Year Scancell Chart |
|
1 Month Scancell Chart |
Intraday Scancell Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/5/2024 | 08:39 | Scancell - Pot of Gold or POS? | 8,479 |
| 24/4/2024 | 11:01 | Scancell investors thread (litter free) | 399 |
| 17/1/2024 | 14:12 | Scancell for investors (inanaco free thread) | 235 |
| 09/12/2023 | 09:53 | Using immunology to fight cancer. | 57,587 |
| 01/12/2023 | 15:26 | Scancell - BS free thread | 2 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-05-03 16:07:32 | 9.15 | 200,000 | 18,300.00 | O |
| 2024-05-03 14:57:01 | 9.25 | 100,000 | 9,250.00 | O |
| 2024-05-03 14:13:57 | 9.22 | 40,043 | 3,691.96 | O |
| 2024-05-03 13:43:55 | 9.22 | 10,000 | 922.00 | O |
| 2024-05-03 13:19:53 | 9.06 | 12,000 | 1,087.20 | O |
| Top Posts |
|---|
Posted at 04/5/2024 09:20 by Scancell Daily Update Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 9.10p.Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £84,895,528. Scancell has a price to earnings ratio (PE ratio) of -7.09. This morning SCLP shares opened at 9.10p |
Posted at 03/5/2024 21:20 by 2tyke Nope the share price is NOT governed by the probability of success or the probability of failure of products.It IS governed by herding traders either trying to make money...or limit losses. The long term investors in love with the company do not play a part in share price movement. They have already acted, usually at the wrong time due to incorrect premise, and are literally tossed around by the price waves. So what do they do ? Complain about the market not understanding their incorrect premise (lol)....comfort eachother that they all have the incorrect premise and so all will be ok in the end (lol)....pray for a takeover ( which is a desperate and very poor reason to hold any stock position). |
Posted at 03/5/2024 08:43 by 2tyke Well you probably won't know this but good 'news' only reinforces an uptrending stock...not a downtrending one. Which is why all the good RNS's are having no effect on this share price It needs to bottom.It's bad news that reinforces a downtrending stocks moves. Might be worth considering how price would move if a bad RNS was released soon. It would probably drop faster than you could say 'inane is a mad-man.' |
Posted at 27/4/2024 16:48 by ivyspivey Inanaco can you please explain why it infers I have no shares as why would I want the share price to go up if I had no shares.There are plenty of positions between having a shed load of shares like yourself and having none and yes I do have a number of shares or else I would simply not post here but that is not a high enough of a number to worry too much about how much the share price May or may not move in either direction. I hope for all SH sake that it comes good here both for patients and SH benefit but there are other shares apart from SCLP |
Posted at 27/4/2024 15:10 by ivyspivey Fair post Ruck as you say we all have a motivation to be here to some extent but it dies amuse me when others portray us individually as belonging to a certain camp when only us know the truth.I frequent these boards as I am invested here and simply want to know as much as possible about my investment by watching the various inputs and making a judgement. I have absolutely no agenda in trying to drive the share price down for any reason despite others assertions. I want the share price to go up but equally am comfortable to wait or even if it went bust or went to £1 it would not impact me hence I don’t post that often Anyway most of the comment action on AIM shares has moved away from BBs to TG groups ( Although the SCLP one is extremely quiet). Anyways always nice to look in and touch base with folks |
Posted at 27/4/2024 14:47 by inanaco same answer really issue 3However, the trial can't and won't morhph into an adjuvant study and you shouldn't be raising expectations that it can. who is giving this impression ? please provide my post that shows this Bermudashorts - 20 Apr 2024 - 22:43:39 - 7885 of 8078 Scancell - Pot of Gold or POS? - SCLP inanaco Your 7883 - I did not separate adjuvant melanoma from stage 4 - what a bizarre takeaway from this debate. The forthcoming phase 2/3 is being run in advanced inoperable melanoma where SCIB1/CPIs are being given as a first line therapy. PFS and OS are standard endpoints in virtually all oncology trials, no matter what setting and clearly the better the response the better those survival results will be. However, the trial can't and won't morhph into an adjuvant study and you shouldn't be raising expectations that it can. Similarly it's utter nonsense to suggest that any phase II/III trial (especially the first randomised study for the drug in question)could have a probability of success of 90% at outset. Finally you are quite right, I don't buy into your 'no risk' fairytale and it's somewhat ironic that in order to highlight this you quote the results of the original SCIB1 study. A trial that took place over a decade ago, when there were only about 200m shares in issue and the results were so good that they were going to lead to a trade sale for many multiples of the market cap. Here we are nearly 14 years later and nearly 1 billion shares in issue and the share price under 10p. No risk indeed. We seem unable to have a reasoned debate and I'm sure have much better things to do with our time. I'll move across to one of the other boards and leave you to get on with it. You should know though that although I reduced my holding, I am still invested and want Scancell to succeed every bit as much as you. |
Posted at 15/4/2024 11:05 by inanaco Glymabs was a spin off from the University as such Scancell seems to get a look in at what they develop and is in a position to transition them to the clinicas further research gets developed we clearly are in the best position bearing in mind that early research eats capital and is very high risk, which is why you need CRUK etc grant funding only moditope was discovered in house the rest developed further in house glymabs and immunobody discovered by Lindy team but working for the UNI if Scancell was to pay Lindy true worth ......... we would be skint ! what would GSK pay ? or even BioNtech we get clouded by the low share price ....... emptyend Posts: 544 Price: 10.10 Strong Buy RE: Probing the expression and adhesion of glycans involved in Helicobacter pylori infectionToday 06:57 This is actually a piece I find a bit concerning as a shareholder. It renews lingering questions in my mind about whether shareholder value is front and centre in the company’s activities, or whether the company is just a bolt-on to a venture which is publicly-funded pure science, being pursued for its own sake. Of couse there is a symbiosis here, but the company itself should be ENTIRELY focused on developing intellectual property and monetising it for the benefit of its shareholders. I’d like to think we would get RNSs soon that prove that is the focus, and not the science alone….. |
Posted at 03/2/2024 19:33 by chilltime On the point of a low share price versus our perception of where we think it should be, Lindy perks up my interest there.Various public companies can irrationally go ballistic on their share price based on hype, being the in thing catching market attention. In the Pharma world it's been the immunotherapy PD1 scene. Antibodies that unmask cancer cells to allow our immune systems to go on the attack and destroy them. Scancell are in the world of the a super boost for the attack with Scib. So it seems nailed on, with positive results that vaccines will become a very hot topic to combine with other treatments. Given the it's all about money, those with a patent cliff would seek any means to extend patents and dominate the market. Hence Lindy points to another company in the sector which she hopes has good results (due in a couple of months) as those results would put companies like Scancell in the spotlight. |
Posted at 31/1/2024 18:11 by markingtime 33p per share, based on "overly conservative" assumptions?Its a damned good job we have some large, well-informed, shareholders because (if Lindy's comments are anywhere near accurate) there must be a high chance of attracting a bidder against a background of a share price that is simply wrong. I'll be surprised if the share price is below 33p by year end (a market cap of about £340mn) |
Posted at 07/12/2023 13:37 by inanaco mia .... add the adjuvant resected market as well ............scancells product will work just as well at this stage as later stage ... its the same cancer after all miavoce Posts: 610 Price: 11.75 No Opinion ISCIB1+ - What is it worth ?Today 13:16 In somewhere between 12 and 18 months Scancell are likely to have enough data to convince big pharma that iSCIB1+ is sufficiently effective to make it worth licensing. So, what will big pharma have to pay and what will Scancell be worth. The market for iSCIB1+ in non resectable melanoma will be $4.5bn (3 x the SCIB1 market size), so let's say that big pharma estimate that can achieve annual sales of $2bn. How much would they have to pay Scancell to buy that future annual revenue stream - my guess would be $1bn up front plus $500m in milestones. They would also need to give a significant royalty to Scancell given the fact that the risk of failure will be low - my guess would be 15%. So, in 2025 Scancell might receive $1bn with the expectation of a further $500m over the following 2-3 years. This would certain push the share price towards the £1 mark irrespective of whatever else may be happening with our other products. Obviously the share price isn't going to stay at 12p until the deal is done - the progressive build up of positive data will make a deal more and more likely and the share price will rise in anticipation (not withstanding what may also be happening - e.g. trial data, deals - with our other products). The real kicker comes in later however when the royalty stream builds. 15% of $2bn is $300m of pure profit for Scancell each year. Based on a PE ratio of just 10 this would give Scancell a valuation of $3bn or around £2 per share and there may also be a decent dividend. And this is just for iSCIB1+ ! As trials progress and deals are done for other products they will only add to the valuation. |
Posted at 01/12/2023 10:05 by ih_486726 But the existing major investors already agreed to participate. A higher placing offer would change nothing for then except the company would issue fewer shares. As for the £2M to be raised from existing and new smaller shareholders, why would you prefer to be more diluted (most of the shares went to the big guys) and buy at 11p with the share price currently at that level, than buying at 14p also with the share price at that level. Plus the positivity a placing slightly above the current share price wouod create.Again there might be good reason for this, I just don't get it :/ |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
